The disclosure provides immunogenic compositions comprising HPV VLPs from one or more HPV types in combination with an adjuvant comprising a TLR agonist for use in a method for the prevention of HPV infection or disease in an individual, wherein a first dose of the immunogenic composition comprising HPV VLPs and a TLR agonist, is administered followed by a second dose of an immunogenic composition comprising HPV VLPs from one or more HPV types but which does not comprise a TLR agonist.
